Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.
Burgermeister E, Höde P, Betge J, Gutting T, Merkel A, Wu W, Tänzer M, Mossner M, Nowak D, Magdeburg J, Rückert F, Sticht C, Breitkopf-Heinlein K, Schulte N, Härtel N, Belle S, Post S, Gaiser T, Heppner BI, Behrens HM, Röcken C, Ebert MPA. Burgermeister E, et al. Among authors: betge j. Oncotarget. 2017 Sep 15;8(49):84714-84728. doi: 10.18632/oncotarget.20950. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156678 Free PMC article.
Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP, Schulte N. Betge J, et al. Digestion. 2016;94(3):129-137. doi: 10.1159/000449412. Epub 2016 Oct 19. Digestion. 2016. PMID: 27756074
Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R. Zuurbier L, et al. Among authors: betge j. Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306. Oncotarget. 2017. PMID: 28487489 Free PMC article.
The drug-induced phenotypic landscape of colorectal cancer organoids.
Betge J, Rindtorff N, Sauer J, Rauscher B, Dingert C, Gaitantzi H, Herweck F, Srour-Mhanna K, Miersch T, Valentini E, Boonekamp KE, Hauber V, Gutting T, Frank L, Belle S, Gaiser T, Buchholz I, Jesenofsky R, Härtel N, Zhan T, Fischer B, Breitkopf-Heinlein K, Burgermeister E, Ebert MP, Boutros M. Betge J, et al. Nat Commun. 2022 Jun 6;13(1):3135. doi: 10.1038/s41467-022-30722-9. Nat Commun. 2022. PMID: 35668108 Free PMC article.
PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.
Gutting T, Hauber V, Pahl J, Klapproth K, Wu W, Dobrota I, Herweck F, Reichling J, Helm L, Schroeder T, Li B, Weidner P, Zhan T, Eckardt M, Betge J, Belle S, Sticht C, Gaiser T, Boutros M, Ebert MPA, Cerwenka A, Burgermeister E. Gutting T, et al. Among authors: betge j. Oncoimmunology. 2021 May 5;10(1):1906500. doi: 10.1080/2162402X.2021.1906500. Oncoimmunology. 2021. PMID: 34026331 Free PMC article.
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Härtel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP. Burgermeister E, et al. Among authors: betge j. EBioMedicine. 2019 Jul;45:139-154. doi: 10.1016/j.ebiom.2019.07.004. Epub 2019 Jul 9. EBioMedicine. 2019. PMID: 31300350 Free PMC article.
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM, Betge J, Gutting T, Burgermeister E, Belle S, Zhan T, Schulte N, Maenz M, Ebert MP, Haertel N. Meindl-Beinker NM, et al. Among authors: betge j. BMC Cancer. 2019 Mar 14;19(1):231. doi: 10.1186/s12885-019-5446-2. BMC Cancer. 2019. PMID: 30871493 Free PMC article. Clinical Trial.
Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors.
Bamberg LV, Heigwer F, Wandmacher AM, Singh A, Betge J, Rindtorff N, Werner J, Josten J, Skabkina OV, Hinsenkamp I, Erdmann G, Röcken C, Ebert MP, Burgermeister E, Zhan T, Boutros M. Bamberg LV, et al. Among authors: betge j. Int J Cancer. 2022 Nov 1;151(9):1586-1601. doi: 10.1002/ijc.34155. Epub 2022 Jun 28. Int J Cancer. 2022. PMID: 35666536 Free article.
48 results